Single-Unit Umbilical Cord Blood Transplantation from Unrelated Donors in Adult Patients with Chronic Myelogenous Leukemia  by Sanz, Jaime et al.
From the
Fe, V
Auto`n
Trasf
Financial d
Correspon
Unive
Camp
Received M
 2010 Am
1083-8791
doi:10.101Single-Unit Umbilical Cord Blood Transplantation
from Unrelated Donors in Adult Patients with Chronic
Myelogenous Leukemia
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Dolores Planelles,3 Luis Larrea,3 Guillermo Martın,1 Javier Palau,1 Isidro Jarque,1
Jesus Martınez,1 Javier de la Rubia,1 Federico Moscardo,1 David Martinez,1 Ines Gomez,1
Marıa Lopez,1 Miguel A. Sanz,1 Guillermo F. Sanz1Clinical studies focused on outcomes of umbilical cord blood transplantation (UCBT) for patients with
chronic myelogenous leukemia (CML) in need of allogeneic stem cell transplantation and lacking an
HLA-matched adult donor are limited. We analyzed the outcome of 26 adults with CML receiving single-
unit UCBT from unrelated donors after myeloablative conditioning at a single institution. Conditioning
regimens were based on combinations of thiotepa, busulfan, cyclophospamide or fludarabine, and antithymo-
cyte globulin. At the timeof transplantation, 7 patients (27%)were in first chronic phase (CP), 11 (42%)were in
second CP, 2 (8%) were in accelerated phase (AP), and 6 (23%) were in blast crisis (BC). The cumulative
incidence (CI) of myeloid engraftment was 88% at a median time of 22 days and was significantly better for
patients receiving higher doses of CD341 cells. The CI of acute graft-versus-host disease (GVHD) grade
II-IV was 61%, that of acute GVHD grade III-IV was 39%, and that of chronic extensive GVHD was 60%.
Treatment-related mortality (TRM) was 41% for patients undergoing UCBTwhile in first or second CP and
100% for patients in AP or BC (P\.01). After a median follow-up of 8 years, none of the patients relapsed,
giving an overall disease-free survival (DFS) at 8 years of 41%. The DFS for patients undergoing UCBTwhile
in anyCPwas 59%. These results demonstrate that UCBT from unrelated donors can be a curative treatment
for a substantial numberof patients withCML. Advances in supportive care and better selection of cord blood
units and patients are needed to improve TRM.
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Allogeneic hematopoietic stem cell transplantation
(HSCT) is no longer the first-line treatment for most
patients with chronic myelogenous leukemia (CML)
because of the high efficacy of tyrosine-kinase inhibi-
tors (TKIs), such as imatinib [1]. However, a number
of patients treated with imatinib will eventually need
second-line treatment [2]. For those patients progress-1Department of Hematology, Hospital Universitario La
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6/j.bbmt.2010.05.014ing to a more advanced phase of the disease and those
in first chronic phase (CP) who fail second-line TKI
therapy or harboring a T315I mutation, allogeneic
HSCT is recommended [3]. Umbilical cord blood
(UCB) could be used as an alternative stem cell source
for patient in whom allogeneic HSCT is indicated and
lack an HLA-matched adult donor.
Very little information exists on the outcome of
patients undergoing UCB transplantation (UCBT)
to treat CML. Only 2 previous studies—a preliminary
report of a small series of patients from our institution
testing feasibility [4] and a recent analysis from the
Japan Cord Blood Bank Network (JCBBN) registry
[5]—have focused on patients with CML. In addition,
some early registry-based studies of patients undergo-
ing UCBT for a variety of hematologic malignancies
suggested a particularly poor outcome for patients
with CML [6,7].
We report the outcome of a series of adult patients
with CML with prolonged follow-up who underwent
UCBTwith a graft from an unrelated donor at a single1589
1590 Biol Blood Marrow Transplant 16:1589-1595, 2010J. Sanz et al.institution. Apart from confirming the feasibility and
efficacy of the procedure in this specific disease, an
additional aim of the study was to identify variables
influencing short-term and long-term outcomes.PATIENTS AND METHODS
Eligibility Criteria
This report constitutes a retrospective review of all
26 consecutive adult patients with CML who under-
went UCBT from unrelated donors at our institution
between May 1997 and July 2009. Patients were eligi-
ble for enrollment if they met the following criteria:
(1) Allogeneic HSCT from an unrelated donor
was considered the best therapeutic option; (2) there
was no suitable related donor (HLA-identical or one-
antigen–mismatched); (3) there was a need for urgent
transplantation or lack of an HLA-identical unrelated
donor after a search of the international registries;
and (4) an there was an available UCB unit fulfilling
the minimum established criteria for both HLA com-
patibility between donor and recipient and cell dose.
In this regard, UCB units had to share at least 4 HLA
antigens with the recipient (HLA class I antigens
[A and B] determined by serologic or low-resolution
DNA typing and class II antigens [DRB1] by high-
resolution DNA typing). In terms of cell dose, a nucle-
ated cell (NC) dose.1.5 107 per kg of recipient body
weight was required until May 2006. Thereafter, insti-
tutional policy required a NC dose.2 107 per kg of
recipient body weight and aCD341 cell dose.1 105
per kg of recipient body weight because of our observa-
tion of the impact of cell dose on outcome.Our Institu-
tional Review Board approved the protocol, and
written informed consent was obtained from all
patients according to the Declaration of Helsinki.UCB Unit Selection and Management
The search for UCB units was conducted by the
Spanish Registry of Bone Marrow Donors (Registro
Espan˜ol de Donantes de Medula Osea). Among the
availableUCBunits fulfilling theminimum established
criteria, units with higher cell dose (considering both
NCs and CD341 cells) and greater HLA compatibility
were selected across the study period. ABOcompatibil-
ity and year of storagewere considered aswell. AllUCB
units tested negative for human immunodeficiency
virus, hepatitis B and C viruses, and human T cell
lymphotropic virus type I. All UCB units and mothers
were negative for immunoglobulin M antibody to
cytomegalovirus (CMV).
UCB units were thawed according to the method
of Rubinstein et al. [8], with minor modifications as
described elsewhere [9]. Before infusion, a sample
was drawn directly from the final bag for cell counts,including CD341 cells [10], cell viability, clonogenic
assays [11], and microbiology.
Conditioning Regimen
All patients received a myeloablative conditioning
regimen based on a combination of thiotepa, busulfan
(Bu), cyclophospamide (Cy), or fludarabine (Flu), and
antithymocyte globulin (ATG) (Table 1). Until No-
vember 2004, 21 patients received thiotepa 5 mg/kg/
day on days 29 and 28, oral Bu 1 mg/kg/6 hours or
i.v. Bu 0.8 mg/kg/6 hours or on days 27 to 25, Cy 60
mg/kg/day on days 24 and –3, and ATG on days 25
to 22. Thereafter, Cy was substituted by Flu in 5 pa-
tients, who received thiotepa 5 mg/kg/day on days 27
and 26, i.v. Bu 3.2 mg/kg as a single daily dose on
days 25 to 23, Flu 50 mg/m2/day on days 25 to 23,
and ATG on days25 to22.
In terms of the type of ATG used, the first 15
patients received horse ATG (Lymphoglobuline;
Merieux, Lyon, France; total dose, 60 mg/kg), and
the subsequent 11 patients received rabbit ATG (Thy-
moglobulin; Sangstat/Genzyme, Lyon, France; total
dose, 8 mg/kg).
Graft-versus-Host Disease Prophylaxis and
Treatment
All patients received cyclosporine 1.5 mg/kg/12
hours i.v., followed by 3-5 mg/kg/12 hours orally
when oral intake was possible, with slow tapering start-
ing between days 190 and 1180 and discontinuation
on day 1180 or before if feasible. Cyclosporine was
combined with prednisone in the first 22 patients
(0.5 mg/kg/day on days 17 to 114 and 1 mg/kg/day
on days 114 to 128, with slow tapering to discontin-
uation on day 1180) [9]. Three patients patients re-
ceived mycophenolate mofetil 15 mg/kg/12 hours
until day 128 and prednisone 1 mg/kg/day on days
114 to 128 in the remaining patient.
Patients who developed acute graft-versus-host-
disease (aGVHD) received high-dose methylpredniso-
lone as initial therapy (20 mg/kg/day, with the dose
halved every 3 days until it reached 1 mg/kg/day, and
tapered gradually thereafter).
Supportive Care
Patients were nursed in high-efficiency particulate
air (HEPA)-filtered rooms. Intravenous access was
achieved with a double-lumen tunneled central venous
catheter. Granulocyte colony-stimulating factor 5 mg/
kg/day was administered s.c. from day17 until neutro-
phil engraftment occurred. All patients received oral
ciprofloxacin 500 mg/12 hours as antibacterial pro-
phylaxis. Prophylaxis against Pneumocystis jiroveci con-
sisted of cotrimoxazole (320/1600 mg trimethoprim/
sulfamethoxazole daily) from day -10 to day -2, and
then restarted after engraftment and maintained for
Table 1. Graft- and Transplantation-Related Characteristics*
HLA compatibility, n (%)
6 of 6 0 (0)
5 of 6 9 (35)
4 of 6 17 (65)
ABO blood group mismatch, n (%)
Major 5 (19)
Minor 5 (19)
None 16 (62)
Donor–recipient sex match, n (%)
Male–male 7 (27)
Male–female 7 (27)
Female–male 8 (31)
Female–female 4 (15)
Year of transplantation, n (%)
1997-2001 17 (65)
2002-2009 11 (35)
Conditioning regimen, n (%)
TT + Bu + Cy + ATG 21 (81)
TT + Bu + Flu + ATG 5 (19)
GVHD prophylaxis, n (%)
Cyclosporine A + prednisone 23 (88)
Cyclosporine A + MMF 3 (12)
Number of NCs before freezing,  107/kg
Median 2.5
Range 1.5-6.9
Number of NCs infused,  107/kg
Median 1.9
Range 1.1-4.9
Number of CD34+ cells before freezing,  105/kg
Median 1.2
Range 0.3-2.2
Number of CD34+ cells infused,  105/kg
Median 0.9
Range 0.3-2.2
TT indicates thiothepa; Bu, busulfan; Cy, cyclophosphamide; Flu,
fludarabine; MMF, mycophenolate mofetil.
*Percentages may not sum to 100 because of rounding.
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suppresion (2 days a week). Fluconazole 100 mg/day
orally was administered as antifungal prophylaxis at
the beginning of the study period. Starting in Novem-
ber 2003, prophylaxis with fluconazole was substituted
by i.v. itraconazole 200 mg/day. All blood products
were irradiated and leukocyte-depleted. CMVprophy-
laxis, infection surveillance, and treatment have been
described in detail elsewhere [12]. Nonspecific i.v. im-
munoglobulin was administered at a dose of 500 mg/
kg weekly up to day 1100 and then monthly during
the first year after transplantation.Definitions
Myeloid engraftment was defined as an absolute
neutrophil count (ANC) of$0.5 109/L on 3 consec-
utive days. Platelet engraftment was defined as a plate-
let count of$20 109/L, without transfusion support,
for 7 consecutive days. Patients who survived for more
than 28 days after transplantation and who failed to
achieve myeloid engraftment were considered graft
failures. Time to myeloid or platelet engraftment was
defined as the time required to reach the first day of
engraftment. aGVHD and chronic GVHD (cGVHD)were defined and graded according to standard criteria
[13-15].Statistical Analysis
The probabilities of engraftment, treatment-
related mortality (TRM), GVHD, and relapse were
estimated by the cumulative incidence (CI) method
(marginal probability) [16]. For CI analysis of engraft-
ment, GVHD, and relapse, death while in complete
remission was considered a competing cause of failure,
whereas for TRM, relapse was considered the compet-
ing event. Unadjusted time-to-event analyses were
performed using the Kaplan-Meier estimate [17],
and, for comparisons, the log-rank test [18]. Disease-
free survival (DFS) was calculated from the date of
UCBT. In the analysis of DFS, relapse and death while
in complete remission, whichever occurred first, were
considered uncensored events. Variables considered
for prognostic factor analysis were age, sex, recipient
CMV serology, disease status at transplantation,
degree of HLA match, donor–recipient sex match,
and NC and CD341 cell dose before freezing and at
infusion. Continuous variables were dichotomized at
the most discriminative cutoff point for each outcome.
The follow-up of the patients was updated on
February 1, 2010. The median follow-up for surviving
patients was 99 months (range, 7-153 months). All
P values reported are 2-sided. Except for the cumula-
tive incidence method, computations were performed
using the appropriate programs from the BMDP
statistical library (BMDP Statistical Software, Los
Angeles, CA) [19].RESULTS
Patient and Disease Characteristics
Table 2 shows the characteristics of the 26 adult
patients with CMLwho underwent UCBT from unre-
lated donors. In brief, 14 patients were males and 12
females with a median age of 33 years (range, 16-48
years). Seven patients (27%) were in first chronic phase
(CP), 11 (42%) were in second CP, 2 (8%) were in
accelerated phase (AP), and 6 (23%) were in blast crisis
(BC) at the time of transplantation.
All 7 patients in first CP were transplanted without
any cytogenetic response; 5 had stable disease, and 2
were in complete hematologic remission. Only one
of these patients had received previous treatment
with imatinib. This patient achieved complete hema-
tologic response, but had no cytogenetic response after
6 months of treatment. The remaining patients who
underwent transplantation while in first CP did so
before imatinib became available. Three patients had
received a mobilization regimen with mini-ICE as
described previously [20], with successful collection
Table 2. Characteristics of Patients with CML Undergoing
UCBT*
Number of patients 26
Age, years
Median 33
Range 16-48
Age group, n (%)
16-20 years 3 (12)
21-30 years 7 (27)
31-40 years 9 (34)
>40 years 7 (27)
Sex, n (%)
Male 14 (54)
Female 12 (46)
Weight, kg
Median 63
Range 45-95
Disease status at transplantation, n (%)
First chronic phase 7 (27)
Second chronic phase 11 (42)
Accelerated phase 2 (8)
Blast crisis 6 (23)
Previous ASCT, n % 4 (15)
CMV serologic status before transplantation, n (%)
Positive 21 (81)
Negative 5 (19)
Time from diagnosis to transplantation
for patients in first CP, months
Median 19
Range 6-40
CML indicates chronic myelogenous leukemia; UCBT, umbilical cord
blood transplantation; ASCT, autologous stem cell transplantation;
CP, chronic phase.
*Percentages may not sum to 100 because of rounding.
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Figure 1. Cumulative incidence of neutrophil recovery after UCBT,
overall and according to the number of CD341 cells at infusion (cutoff,
0.6  105/kg).
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stored and used as a backup. The median time from
diagnosis to transplantation for patients undergoing
transplantation while in first CPwas 19months (range,
6-40 months).
Of the 11 patients undergoing transplantation
while in second CP, 2 had a previous AP (1 at diagnosis
and 1 after imatinib failure) and received an autologous
stem cell transplantation (ASCT) to achieve a second
CP. The remaining 9 patients had a previous BC, 5
of lymphoid lineage and 4 of myeloid lineage (in 5
patients at initial diagnosis and in 4 after a first CP).
To restore second CP, 4 patients received imatinib, 3
patients received acute myelogenous leukemia (AML)-
type chemotherapy, and 1 patient received a combina-
tion of AML-type chemotherapy and imatinib.
Two patients underwent UCBT while in AP (1 at
presentation and 1 progressing from a CP after
ASCT). The remaining 6 patients underwent trans-
plantation while in BC. All of these patients had
received chemotherapy in an attempt to revert to CP.
In 3 of these patients, BC was present at diagnosis; 2
patients relapsed to second BC after initial response
to chemotherapy, and 1 patient had refractory disease.
In the other 3 patients, BC developed during the
course of the disease, after ASCT in 1 patient and after
hydroxyurea and interferon therapy in 1 patient. The
third patient, who had a T315I mutation, developedBC on imatinib and relapsed to second BC after initial
response to chemotherapy.Cord Blood Unit and Transplant Characteristics
Table 1 shows the characteristics of UCB units and
those related to the transplantation procedure. All
patients received an HLA-mismatched UCB unit. Do-
nor–recipient disparity in 1 and 2 of 6 HLA antigens
was present in 9 patients (35%) and 17 patients
(65%), respectively. The median number of NCs and
CD341 cells infused was 1.9  107/kg (range, 1.1-
4.9  107/kg) and 0.9  105/kg (range, 0.3-2.2 
107/kg), respectively. Five patients (19%) received
UCB units with a major ABO blood group mismatch.
Eight male patients (31%) received a UCB unit from
a female donor.Myeloid and Platelet Engraftment
One patient died on day 10 after UCBT without
evidence of myeloid engraftment. Two other patients
required special considerations; 1 patient who under-
went transplantation while in CP died on day 25 with-
out evidence of myeloid engraftment with complete
lack of donor chimerism and was considered a graft
failure, and 1 patient died on day 47 with an ANC of
0.4  109/L and detection of full donor chimerism
and was considered to have a competing event for
engraftment. The remaining 23 patients experienced
myeloid engraftment at a median time of 22 days
(range, 13-52 days). The CI of myeloid engraftment
was 88% at 52 days (Figure 1). All patients with mye-
loid engraftment demonstrated full donor chimerism
at the time of reconstitution.
The only variable influencing the time to myelog-
enous engraftment was CD341 cell dose at infusion,
with a best cutoff at 0.6  105/kg (Figure 1). The CI
rates of myeloid engraftment for patients receiving
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Figure 2. Cumulative incidence of TRM according to disease stage at
UCBT.
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Figure 3. Kaplan-Meier estimates of DFS according to disease stage at
UCBT.
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105/kg were 95% and 60%, respectively (P 5 .02).
Twelve patients died between 10 and 154 days after
UCBT without platelet engraftment. The remaining
14 patients had platelet engraftment at a median of 67
days (range, 29-188 days). The cumulative incidence
of platelet engraftment was 54% at 188 days.
GVHD
All patients developed some grade of aGVHD
(grade I in 7 patients, grade II in 7, grade III in 5, and
grade IV in 5). The median time to the development
of acute GVHD grade II-IV was 14 days (range, 8-
38). The CI of grade II-IV and grade III-IV aGVHD
at day 100 afterUCBTwas 61%and39%, respectively.
Skin involvement was observed in 23 patients (grade II
in 14, grade III in 2, and grade IV in 1), intestinal in-
volvement was seen in 9 patients (grade II in 2 and
grade IV in 4), and liver involvement was seen in 14 pa-
tients (grade II in 1, grade III in 3, and grade IV in 4).
Four patients died of acute GVHD grade IV.
Eleven of 16 patients at risk developed cGVHD
(limited in 2 patients and extensive in 9 patients).
The median time to development of cGVHD was
214 days (range, 96-385 days), and the 2-year CI of ex-
tensive cGVHD was 60%. Four of 9 patients with ex-
tensive cGVHD (45%) had complete resolution and
discontinuation of immunosuppressive therapy.
TRM and Causes of Death
Fifteen transplantation-related deaths occurred at
a median time of 56 days after transplantation (range,
10-681 days). The causes of death were infection in 6
patients, GVHD in 5 patients (4 aGVHD and 1
cGVHD), hemorrhage in 2 patients, encephalitis of
unknown cause in 1 patient, and veno-occlusive disease
in 1 patient. Three of the 6 deaths attributable to infec-
tion were bacterial infections (2 with Acinetobacter bau-
manii and 1 with Staphylococcus aureus), 1 was an
adenovirus infection with invasive aspergillosis, and 1
was interstitial pneumonia without microbiological
isolation. The distribution of causes of death did not
differ between patients who underwent transplanta-
tion while in CP and those who underwent transplan-
tation while in AP or BC.
The CI of TRM was 38% at day 100, 50% at 1
year, and 59% at 8 years. The only variable influencing
TRM was disease stage at time of transplantation; the
CI of TRM at 8 years was 41% for patients undergoing
UCBTwhile in first or second CP and 100% for those
undergoing UCBT while in AP or BC (P \.01)
(Figure 2).
Relapse and DFS
No hematologic, cytogenetic, or molecular re-
lapses were observed during the study period. Elevenpatients remained alive and leukemia-free after
UCBT at last follow-up. The overall DFS at 8 years
was 41% (95% confidence interval, 21%-61%).
For patients in first CP, 3 of 7 remained CML-free
after 129, 130, and 135 months of follow-up, with an
8-year DFS of 43%. Eight of 11 patients who under-
went transplantation while in second CP remain alive
and leukemia-free, with an 8-year DFS of 69%.
Overall, DFS at 8 years was 59% (95% confidence
interval, 37%-81%) for patients undergoing UCBT
while in any CP, compared with 0% for those under-
going transplantation while in AP or BC (P \.001)
(Figure 3).DISCUSSION
This single-center study with long-term follow-up
confirms that single-unit UCBT from unrelated do-
nors after myeloablative conditioning is a feasible
alternative for adults with CMLundergoing transplan-
tation while in CP. The absence of relapses in our
patients confirms the high efficacy of the procedure,
although it is hampered by high TRM. We also were
able to identify CD341 cell dose at time of infusion
1594 Biol Blood Marrow Transplant 16:1589-1595, 2010J. Sanz et al.as the main factor associated with myeloid recovery.
Although the relatively small sample size and the retro-
spective nature of this study are limitations, these data
may provide clinically useful information to improve
the outcome of UCBT in adults with CML in need of
allogeneic HSCT through better selection of both
UCB grafts and recipients.
Apart from a previous report from our group de-
scribing the preliminary data from a series of 9 patients
undergoing UCBT [4], only 1 study using data from
the JCBBN registry has focused on patients with
CML [5]. Thus, we discuss our results in the context
of this limited information on UCBT in patients
with CML. Moreover, because of the special charac-
teristics of the sample population, our results cannot
be extrapolated to those obtained after HSCT using
other stem cell sources or donors.
In contrast with the sole previous report on UCBT
in CML by Nagamura-Inoue et al. [5], which was
based on registry data, our study analyzed a homoge-
nous population of adults undergoing busulfan-based
myeloablative conditioning with closely similar
GVHD prophylaxis and supportive care at a single in-
stitution. It should be taken into account that the vast
majority of transplantations were performed before
2002, the early period of UCBT activity, when quality
programs for processing and cryopreserving UCB
units, as well as the criteria for unit selection and opti-
mization of clinical management, were not yet well
established. It should also be considered that, similar
to previous studies, most of the patients were heavily
pretreated and underwent transplantation in a very
advanced phase of disease.
Our study found ahigh rate ofmyeloid engraftment
with rapid neutrophil recovery using single-unit UCB
that compares favorably with other registry data
[5-7]. Rubinstein et al. [6] reported a significantly re-
duced likelihood of successful engraftment in patients
with CML, comparable to that seen in patients with
Fanconi’s anemia and severe aplastic anemia. The
study by the JCBBN also reported a worse-than-
expected myeloid engraftment, with a CI of neutrophil
recovery of 68% at a median time of 24 days and a graft
failure rate of 17% [5]. However, in the current series,
the CI of neutrophil recovery was 88% at a median of
22 days, with only 1 patient demonstrating graft failure.
Again, CD341 cell dose was significantly associated
with the speed and rate of engraftment, as reported
previously by us and others [21-23].
The apparently higher incidence of aGVHD in
this series compared with that previously reported by
us in patients with AML undergoing UCBT [22]
merits some comment. A possible explanation could
be the substantially higher proportion of patients
with CML who received horse ATG instead of rabbit
ATG in the conditioning regimen, because of the fact
that most of them underwent transplantation at the be-ginning of the UCBT program at our center. In fact,
unpublished data from our institution suggest that
the type of ATG has a clear impact on the risk of
aGVHD. Nevertheless, an intrinsic susceptibility to
the development of GVHD in patients with CML
compared with patients with other malignant diseases
cannot be ruled out, given that this has been reported
after UCBT [7] and bone marrow (BM) HSCT [24].
Although we possibly could have underestimated
the risk of relapse because of the elevated TRM, it is
noteworthy that all 11 patients who survived UCBT
(8 of whom underwent transplantation while in second
CP after previous BC) remained CML-free after a me-
dian follow-up of around 8 years. This finding suggests
a powerful graft-versus-leukemia effect after UCBT,
as has been observed after unrelated donor allogeneic
BM or peripheral blood HSCT [25]. However, the re-
lapse rate seems to be significantly different than that
reported for T cell–depleted grafts [26]. This is a par-
ticularly important observation, because the low lym-
phocyte content of UCB grafts and the lower
incidence of GVHD after UCBT compared with
transplantation with other stem cell sources led to
early concerns regarding a possible increased risk of
relapse.
Our overall results in terms ofDFSwere influenced
by TRM and the associated risk factors. TRM was rel-
atively high, particularly in patients undergoing trans-
plantation while in BC or AP, as has been described in
all series including patients with CML [5-7]. A
Eurocord analysis of 171 adults undergoing UCBT
for a variety a hematologic malignancies found
a significantly higher 2-year CI of TRM (76%) in
patients with CML compared with those with other
malignant diseases [7].Moreover, theNewYork Blood
Center reported that the overall incidence of
transplantation-related events other than relapse were
negatively correlated with the recipient’s diagnosis of
CML [6]. A possible explanation for this finding is
the advanced phase of the disease and the cumulative
drug-related toxicity at the time of transplantation for
the vast majority of patients. In addition, we should
consider that most transplantations were performed
in the early period of UCBT, before the imatinib era.
Thus, those results should be interpreted cautiously,
because they do not necessarily reflect current practice.
It is likely that pretransplantation imatinib mesylate
will reduce the TRM rates in more recent years by re-
ducing the tumor burden at the time of transplantation
and by avoiding exposure to more toxic treatments, as
has been described in the unrelated donor BM trans-
plantation setting [27,28].
In conclusion, our study shows that single-unit
UCBT from an unrelated donor after myeloablative
conditioning can be a curative treatment for a substan-
tial number of patients with CML in need of HSCT.
Because of its impact on engraftment, CD341 cell
Biol Blood Marrow Transplant 16:1589-1595, 2010 1595Umbilical Cord Blood Transplantation in CMLdose should be considered when selecting UCB units.
Because TRM is the most important limitation of the
procedure, advances in supportive care and better
selection of UCB units and patients are needed. More
specific studies in adults with CML undergoing
UCBT from unrelated donors are warranted to defi-
nitely establish the role of the procedure in theTKI era.ACKNOWLEDGMENTS
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